复星医药(600196.SH)：复方聚乙二醇(3350)电解质散药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Polyethylene Glycol (3350) Electrolyte Solution by the National Medical Products Administration, aimed at treating chronic constipation [1] Company Summary - Fosun Pharma's Polyethylene Glycol (3350) Electrolyte Solution is a chemical drug intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The expected sales revenue for Polyethylene Glycol Electrolyte Solution in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 873 million in 2024 according to IQVIA CHPA data [1]